September 17, 2015
1:00 - 2:00pm EDT
via Legacy Project's Women's HIV Research Collaborative (WHRC)
According to the Centers for Disease Control nearly one in four people living with HIV in the United States are women. Federal funding has been allocated to increase awareness and inclusion of women and girls in clinical trials, yet female participants are often underrepresented in HIV prevention and treatment research.
Please join the Legacy Project's Women's HIV Research Collaborative (WHRC) for the first of a two-part series highlighting best practices for engagement, recruitment, and retention of female participants in HIV clinical research.
The first webinar will feature Dr. Katherine Bunge from the Microbicide Trials Network (MTN). Dr. Bunge was Co-Chair of MTN-023, a Phase 2a study assessing the safety and acceptability of the dapivirine ring as prevention among adolescent females. The study is conducted in parallel with two Phase 3 trials of the ring and designed to support potential licensure.
We will also hear from Dr. Judith Currier from the AIDS Clinical Trials Group (ACTG). Dr. Currier, Vice Chair of the ACTG, will present on ACTG 5257, a Phase 3 treatment study that paused male enrollment to ensure women were sufficiently represented in the trial. Both studies demonstrate some of the unique considerations that are necessary for successfully engaging women and girls in HIV research.
Click here to register.
The Women's HIV Research Collaborative (WHRC), a working group of the Legacy Project, provides culturally appropriate leadership in development, implementation and dissemination of information about HIV research addressing the needs of women and girls in the United States. The WHRC works to raise the visibility of issues related to HIV in women in the U.S. and promotes awareness of scientific research to women in disproportionately impacted communities.
